APA (7th ed.) Citation

Spigel, D. R., Burris, H. A., Greco, F. A., Shih, K. C., Gian, V. G., Lipman, A. J., . . . Burris, H. A. 3. (2018). Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures. Cancer (0008543X), 124(11), 2355. https://doi.org/10.1002/cncr.31290

Chicago Style (17th ed.) Citation

Spigel, David R., et al. "Erlotinib Plus Either Pazopanib or Placebo in Patients with Previously Treated Advanced Non-small Cell Lung Cancer: A Randomized, Placebo-controlled Phase 2 Trial with Correlated Serum Proteomic Signatures." Cancer (0008543X) 124, no. 11 (2018): 2355. https://doi.org/10.1002/cncr.31290.

MLA (9th ed.) Citation

Spigel, David R., et al. "Erlotinib Plus Either Pazopanib or Placebo in Patients with Previously Treated Advanced Non-small Cell Lung Cancer: A Randomized, Placebo-controlled Phase 2 Trial with Correlated Serum Proteomic Signatures." Cancer (0008543X), vol. 124, no. 11, 2018, p. 2355, https://doi.org/10.1002/cncr.31290.